share_log

BioVie | 424B5: Prospectus

BioVie | 424B5: Prospectus

BioVie | 424B5：募资说明书
美股SEC公告 ·  10/29 11:38

Moomoo AI 已提取核心信息

BioVie Inc., a clinical-stage company focusing on the development of drug therapies for liver disease and neurological disorders, has announced the offering of 1,146,000 shares of its Class A common stock. The shares are being offered at a price of $2.83 per share, with ThinkEquity LLC acting as the exclusive placement agent for the offering. ThinkEquity LLC is not purchasing or selling any securities but will use reasonable efforts to arrange for the sale. The placement agent has agreed to a placement agent fee as outlined in the offering's terms. The proceeds from the offering are expected to be used for working capital and general corporate purposes. The offering is expected to close on or about October 29, 2024, subject to customary...Show More
BioVie Inc., a clinical-stage company focusing on the development of drug therapies for liver disease and neurological disorders, has announced the offering of 1,146,000 shares of its Class A common stock. The shares are being offered at a price of $2.83 per share, with ThinkEquity LLC acting as the exclusive placement agent for the offering. ThinkEquity LLC is not purchasing or selling any securities but will use reasonable efforts to arrange for the sale. The placement agent has agreed to a placement agent fee as outlined in the offering's terms. The proceeds from the offering are expected to be used for working capital and general corporate purposes. The offering is expected to close on or about October 29, 2024, subject to customary closing conditions. BioVie's common stock is traded on The Nasdaq Capital Market under the symbol 'BIVI.' As of October 28, 2024, the aggregate market value of BioVie's outstanding common stock held by non-affiliates was approximately $47.7 million. The company has previously sold approximately $12.67 million of securities in the 12 months preceding the date of the prospectus supplement, excluding the current offering.
biovie公司，一家临床阶段的公司，专注于开发治疗肝病和神经系统疾病的药物疗法，宣布发行114.6万股A类普通股。股票价格为每股2.83美元，ThinkEquity LLC担任独家配置代理人。 ThinkEquity LLC不购买或出售任何证券，但将尽合理努力安排销售。配置代理人已同意按照发行条款支付配置代理人费用。发行所得预计将用于营运资金和一般公司用途。 预计发行将于2024年10月29日左右结束，视常见的结算条件而定。biovie公司的普通股在纳斯达克资本市场以“BIVI”为标的进行交易。截至2024年10月28日，biovie公司的普通股非关联方持有的总市值约为4770万美元。该公司在发行补充说明书日期之前的12个月内已销售约1267万美元的证券，不包括当前发行的。
biovie公司，一家临床阶段的公司，专注于开发治疗肝病和神经系统疾病的药物疗法，宣布发行114.6万股A类普通股。股票价格为每股2.83美元，ThinkEquity LLC担任独家配置代理人。 ThinkEquity LLC不购买或出售任何证券，但将尽合理努力安排销售。配置代理人已同意按照发行条款支付配置代理人费用。发行所得预计将用于营运资金和一般公司用途。 预计发行将于2024年10月29日左右结束，视常见的结算条件而定。biovie公司的普通股在纳斯达克资本市场以“BIVI”为标的进行交易。截至2024年10月28日，biovie公司的普通股非关联方持有的总市值约为4770万美元。该公司在发行补充说明书日期之前的12个月内已销售约1267万美元的证券，不包括当前发行的。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间